

DRAGANA LAKIĆ

Employment Information:

Associate professor, 2018 – onwards

Department of Social Pharmacy and Pharmaceutical Legislation
Faculty of Pharmacy, University of Belgrade, Serbia

Assistant professor, 2013 - 2018

Department of Social Pharmacy and Pharmaceutical Legislation
Faculty of Pharmacy, University of Belgrade, Serbia

Visiting professor, 2013 - 2015

Faculty of Medicine, University of Banja Luka, Bosna and Hercegovina

Teaching and research assistant, 2006 - 2013

Department of Social Pharmacy and Pharmaceutical Legislation
Faculty of Pharmacy, University of Belgrade, Serbia

Medical representative, 2004 - 2006

Eli Lilly (Suisse) S.A., Representative office Belgrade, Serbia

Licensed pharmacist, 2003 - 2004

Community pharmacy “Sanyfarm”, Belgrade, Serbia

Teaching assistant, 2002 - 2003

Department of Drug Analysis
Faculty of Pharmacy, University of Belgrade, Serbia

Education:

PgCert in Medical Education, 2018

Medical Education programme
Centre for Medical Education, University of Dundee, United Kingdom

Specialist in Pharmacy, 2015

Specialist academic studies: Pharmaceutical Management and Marketing
Faculty of Pharmacy, University of Belgrade, Serbia

PhD in Biomedicine, 2012

PhD thesis: Pharmacoeconomics of cardiovascular disease
Faculty of Pharmacy, University of Ljubljana, Slovenia

Specialist in Pharmacy, 2010

Specialist academic studies: Pharmacoeconomics and Pharmaceutical Legislation
Faculty of Pharmacy, University of Belgrade, Serbia

Master of Pharmacy, 2002

Faculty of Pharmacy, University of Belgrade, Serbia

Academic awards and distinctions:

- Second best poster presentation at the National Congress of pharmacist in 2011.

Teaching activities:

- Undergraduate courses: Introduction to Pharmacy, Pharmaceutical Supply Chain Management, Pharmacoepidemiology and Pharmacoeconomics, Pharmaceutical Practice
- Postgraduate courses: at academic specialization Pharmacoeconomics and Pharmaceutical Legislation and doctoral studies field: Social Pharmacy and Pharmacy Practice research
- Mentor and/or member in Committees for undergraduate and postgraduate students. In last five years, mentor in 63 undergraduate thesis and 54 specialists, postgraduate thesis; member of Committee in three PhD thesis

Textbooks:

- 4 textbooks for undergraduate and postgraduate students (Introduction to Pharmacy, Pharmacy Practice).

Activities within the Faculty:

- Member of the Postgraduate Committee – academic specializations (2016 – onwards)
- President of Educational Committee at Faculty of Pharmacy, University of Belgrade (2016 – 2019)
- Member of the working group for the development of the students professional training (2018 -2019)

Activities within wider Academic Community:

- Monitoring the professional pharmacist activities in health (2018 - 2019)
- Member of the special working group at the Ministry of Health for Health Technology Assessment (2018 - 2019)
- Member and vice-president of the Pharmacoeconomic Committee at the Serbian Health Insurance Fund (2008 - 2016)
- Member of the Pharmaceutical Chamber of Serbia (ID No: 3762)
- Member of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR)
- Peer-reviewer for national and international journals

Projects:

- 2011 – onwards: Ministry of education, science and technological development of Serbia (basic research in the field of medicine) *Interactive role of dyslipidaemia, oxidative stress and inflammation in atherosclerosis and other diseases: genetic and biochemical markers* (project No: 175035)
- 2015 – 2018: Erasmus+ project “Reinforcement of the Framework for Experiential Education in Healthcare in Serbia” (project No: 561644-EPP-1-2015-1-RS-EPPKA2-CBHE-JP)
- 2010 – 2013: Tempus project “Postgraduate Qualification in Pharmacy - The Way Forward” (project No: 158897-TEMPUS-1-2009-1-RS-TEMPUS-JPCR)
- 2008 – 2011: Ministry of education, science and technological development of Serbia (basic research in the field of medicine) *Investigation of biochemical and genetic risk factors as causes and markers of atherosclerosis and other diseases: clinical and analytical aspects* (project No: 145036)

Publications:

- Milenković J, **Lakić D**. Analysis of the economic situation of the south east European pharmaceutical industry, *J Med Econ* 2020; 23(9): 932-9.
- Kamuseva M, Lakić D, Petrova G, Beslija S, Culig J. Comparative analysis of the access to health care services and breast cancer therapy in 10 Eastern European countries. *SAGE Open Medicine* 2020; 8: 1-10.
- Kamuseva M, Manova M, Savova AT, Petrova GI, Mitov G, Harsányi A, Kalo Z, Márky K, Kawalec P, Angelovska B, **Lakić D**, Tesar T, Draganic P, Geitona M, Hatzikou M, Paveliu MS, Männik A. Comparative analysis of legislative requirements about patients’ access to biotechnological drugs for rare diseases in Central and Eastern European Countries. *Frontiers in Pharmacology* 2018; 9: 795.

- **Lakic D**, Stevic I, Odalovic M, Vezmar-Kovacevic S, Tadic I. Patients' willingness to pay for cognitive pharmacist services in community pharmacies. *Croat Med J* 2017; 58 (5): 364-71
- Odalovic M, Tadic I, **Lakic D**, Nordeng H, Lupattelli A, Tasic Lj. Translation and factor analysis of structural models of Edinburgh Postnatal Depression Scale in Serbian pregnant and postpartum women – Web-based study. *Women Birth* 2015; 28(3): e31-5. (IF = 1,525)
- Petrovic S, Bogavac-Stanojevic N, **Lakic D**, Peco-Antic AE, Vulicevic I, Ivanisevic I, Kotur-Stevuljevic JM, Jelic-Ivanovic Z. Cost-effectiveness analysis of acute kidney injury biomarkers in pediatric cardiac surgery. *Biochemia Medica* 2015; 25 (2): 262-71.
- **Lakić D**, Tasić Lj, Kos M. Economic burden of cardiovascular diseases in Serbia. *Vojnosanit Pregl* 2014; 71 (2): 137-43.
- **Lakić D**, Petrović B, Petrova G. A cost-effectiveness analysis of different types of labor for singleton pregnancy – real life data. *Srp Arh Celok Lek* 2014; 142(11-12): 688-94
- Bogavac-Stanojevic N, Dopsaj V, Jelic-Ivanovic Z, **Lakić D**, Vasić D, Petrova G. Economic evaluation of different screening alternatives for patients with clinically suspected acute deep vein thrombosis. *Biochemia Medica* 2013; 23 (1): 96-106.